Results 221 to 230 of about 24,787 (310)

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

, 2019
Lieneke F.M. Ariëns, Abhijit Gadkari, Harmieke van Os‐Medendorp, Rajeev Ayyagari, Emi Terasawa, Andreas Kuznik, Zhen Chen, Gaëlle Bégo-Le Bagousse, Yufang Lü, E. Rizova, Neil M.H. Graham, Gianluca Pirozzi, Marjolein de Bruin‐Weller, Laurent Eckert   +13 more
openalex   +2 more sources

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1350-1361, May 2026.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Long-Term Clinical Improvement of Severe Atopic Dermatitis Refractory to Dupilumab After Intramuscular Injections of Autologous Total Immunoglobulin G: A Case Report. [PDF]

Allergy Asthma Immunol Res
Nahm DH, Kim ME.
europepmc   +1 more source

Assessing Nasal Obstruction Improvement in Dupilumab-Treated Patients With Active Anterior Rhinomanometry: A Preliminary Study

Francesco Giombi, Gian Marco Pace, Giulia Mari, Michele Cerasuolo, Giulio Sandri, Luca Cerri, Enrico Heffler, Giovanni Paoletti, Francesca Puggioni, Giuseppe Mercante, Giuseppe Spriano, Luca Malvezzi   +11 more
openalex   +1 more source

<p>Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps</p>

, 2020
Harsha H. Kariyawasam, Louisa K. James, Simon Gane   +2 more
openalex   +2 more sources

Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

JPGN Reports, Volume 7, Issue 2, Page 185-191, May 2026.
Abstract Objectives Eosinophilic esophagitis (EoE) is a type 2 cytokine‐mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL‐4 and IL‐13 signaling, which are key inflammatory mediators in EoE and other allergic disorders.
Sindhura Kasturi, Tanaz Danialifar, Thirumazhisai Gunasekaran, Nick Shillingford, Paul Zamiara, Vrinda Bhardwaj, Melinda Braskett   +6 more
wiley   +1 more source

Efficacy of Dupilumab in Treating Trachyonychia and Other Nail Dystrophies: A Systematic Review of Case Reports. [PDF]

Cureus
Alhazmi SA, Albyali S, Alanazi R, Alhejaili BS, Alqahtani AS, Altowairqi RK, Mousa Altamimi R, Alzahrani NM, Alamoudi B, Alsweed KA, Kurdi R, Hajjaj HS, Firdous R, Samhan LM, Al-Modayfer AO.   +14 more
europepmc   +1 more source

Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study [PDF]

Tiago Torres, Maria João Cruz, Margarida Gonçalo, Paulo Filipe, Bruno Duarte, João Alves, José Miguel Alvarenga, Gilberto Pires da Rosa, Duarte Flor, José Ramos, Diogo de Sousa, Aureliu Rosca, César Magalhães, Cristina Claro, Joana Rocha, Catarina Vilarinho, Fernando Mota, Alberto Mota, Maria João Paiva Lopes   +18 more
openalex   +1 more source

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E. Myers, Pinaki Biswas, Irene Hernández‐Martín, Erman Güler, Marina Mikheil, Raj Chovatiya   +10 more
wiley   +1 more source

Benralizumab for anti‐tumor necrosis factor‐associated eosinophilic gastrointestinal disease in a child with ileal Crohn's: A case report

JPGN Reports, Volume 7, Issue 2, Page 312-314, May 2026.
Abstract Crohn's disease (CD) and eosinophilic gastrointestinal diseases (EGIDs) are distinct inflammatory entities, but eosinophilic disease may emerge as a paradoxical immune complication of anti–tumor necrosis factor therapy. We report a 12‐year‐old boy with terminal ileal CD who developed severe eosinophilic gastritis and ileitis, peripheral ...
Jonathan Dudzik, Alberto Pinzon‐Charry, Peter Lewindon, Fariha Balouch   +3 more
wiley   +1 more source